TIBET PHARMA(SH:600211) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-12-19 10:21Core Viewpoint - The company plans to repurchase shares with a total amount between RMB 170 million and RMB 200 million to implement an employee stock ownership plan and enhance long-term incentive mechanisms [2][3][8]. Group 1: Repurchase Plan Details - The repurchase will be funded by the company's own funds [3][14]. - The maximum repurchase price is set at RMB 55 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [3][13]. - The repurchase will be conducted through centralized bidding on the Shanghai Stock Exchange [4][9]. Group 2: Implementation Timeline and Conditions - The repurchase period will not exceed 12 months from the board's approval date [4][9]. - The repurchase may be completed earlier if the maximum funding limit is reached or if the board decides to terminate the plan [10]. Group 3: Shareholder and Management Plans - There are no plans for share reduction by directors, senior management, or major shareholders in the next three to six months [4][16]. - The company assures that there are no conflicts of interest or insider trading related to the repurchase plan [16]. Group 4: Financial Impact and Future Plans - As of September 30, 2025, the company's total assets are RMB 5.816 billion, with net assets of RMB 3.551 billion [15]. - The repurchase funds, at the upper limit of RMB 200 million, would represent 3.44% of total assets and 5.63% of net assets, indicating a manageable impact on the company's financials [15]. - The repurchased shares are intended for employee stock ownership plans, which are expected to enhance employee motivation and align interests between shareholders and employees [8][15].